Aliases & Classifications for Uveal Diseases

MalaCards integrated aliases for Uveal Diseases:

Name: Uveal Diseases 53 73


External Ids:

UMLS 73 C0042161

Summaries for Uveal Diseases

MalaCards based summary : Uveal Diseases is related to diphtheria and uveitis, and has symptoms including eye manifestations and mydriasis. The drugs Ranibizumab and Infliximab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and liver.

Related Diseases for Uveal Diseases

Diseases related to Uveal Diseases via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 diphtheria 9.6
2 uveitis 9.6
3 retinitis 9.6

Symptoms & Phenotypes for Uveal Diseases

UMLS symptoms related to Uveal Diseases:

eye manifestations, mydriasis

Drugs & Therapeutics for Uveal Diseases

Drugs for Uveal Diseases (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 342)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 347396-82-1 459903
Infliximab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 170277-31-3
Heparin Approved, Investigational Phase 4,Phase 2 9005-49-6 772 46507594
Ganciclovir Approved, Investigational Phase 4,Not Applicable 82410-32-0 3454
Verteporfin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 129497-78-5
Timolol Approved Phase 4,Phase 3,Not Applicable 26839-75-8 33624 5478
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
Iodine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 7553-56-2 807
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
Mycophenolic acid Approved Phase 4,Phase 3,Not Applicable 24280-93-1 446541
Azathioprine Approved Phase 4,Phase 2,Not Applicable 446-86-6 2265
Latanoprost Approved, Investigational Phase 4,Not Applicable 130209-82-4 5282380 5311221
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Not Applicable 128794-94-5 5281078
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 67-73-2 6215
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
Povidone Approved Phase 4,Not Applicable 9003-39-8
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 299-42-3 9294
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 90-82-4 7028
Chlorambucil Approved Phase 4 305-03-3 2708
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 50-18-0, 6055-19-2 2907
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
Difluprednate Approved Phase 4,Phase 3,Phase 2 23674-86-4 443936
Travoprost Approved Phase 4,Phase 3,Not Applicable 157283-68-6 5282226
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
Fluprednisolone Approved Phase 4,Phase 3,Phase 2 53-34-9
Ofloxacin Approved Phase 4 82419-36-1 4583
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
Certolizumab pegol Approved Phase 4 428863-50-7
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
Lactitol Investigational Phase 4,Not Applicable 585-86-4 3871
Bromfenac Approved July 1997 Phase 4 91714-94-2 60726
Maleic acid Experimental Phase 4,Phase 2 110-16-7 444266
44 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Phase 1
45 cadexomer iodine Phase 4,Phase 2,Phase 1,Not Applicable
46 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 calcium heparin Phase 4,Phase 2
48 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
49 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 636)
# Name Status NCT ID Phase Drugs
1 Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT02033018 Phase 4 Aflibercept Injection
2 Evaluating Results of Neusidl Corneal Inserter in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) Unknown status NCT01357122 Phase 4
3 Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema Unknown status NCT02598869 Phase 4 Triamcinolone Acetonide
4 Ranibizumab for Myopic Neovascularization Unknown status NCT01246089 Phase 4 ranibizumab injection
5 Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial) Unknown status NCT02092532 Phase 4 Rescue Intravitreal Aflibercept Injection
6 Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
7 Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis Unknown status NCT01669447 Phase 4
8 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4 methylorednisolone
9 Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis Completed NCT00589628 Phase 4 infliximab;infliximab
10 Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment Completed NCT00543296 Phase 4 0.59 mg Fluocinolone Acetonide implant
11 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
12 Assessing Cosopt Switch Patients Completed NCT00273442 Phase 4 timolol maleate;dorzolamide/timolol maleate fixed combination
13 Aqueous Flare of a Hydrophobic Acrylic Single-piece Open-loop IOL With Modified Material Surface Properties Completed NCT01767012 Phase 4
14 A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery Completed NCT00170729 Phase 4 Prednisolone acetate
15 The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil Completed NCT03144596 Phase 4 Alfuzosin Hydrochloride 10 MG;Tamsulosin Hydrochloride 0.4 MG
16 Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification Completed NCT03321253 Phase 4
17 Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG Completed NCT01978015 Phase 4 travoprost and timolol maleate fixed combination;latanoprost and maleate timolol fixed combination;bimatoprost and timolol maleate fixed combination;dextran and hypromellose
18 Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery Completed NCT02137161 Phase 4 Dexamethasone+Tobramycin eye drop;Bromfenac eye drop
19 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
20 Bevacizumab Intravitreal for Myopic Choroidal Neovascularization Completed NCT00797992 Phase 4 Injection
21 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
22 SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia Completed NCT03409250 Phase 4 Ranibizumab, Lucentis
23 Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD Completed NCT03393767 Phase 4 Ranibizumab
24 Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation Completed NCT03133767 Phase 4 Lactated Ringer Solution;Normal Saline 0.9% Infusion Solution Bag
25 Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration. Completed NCT01831947 Phase 4
26 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab Completed NCT01810042 Phase 4 ranibizumab
27 Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Primarily Intra-retinal Fluid) Treatment. Completed NCT01972789 Phase 4 Ranibizumab
28 Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT) Completed NCT01006538 Phase 4 Ranibizumab
29 Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration Completed NCT01628354 Phase 4 Ranibizumab
30 Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) Completed NCT01148511 Phase 4 Ranibizumab 0.5 mg
31 Photodynamic Therapy in Occult-Only Lesions (POOL) Completed NCT00135837 Phase 4 Verteporfin for injection
32 Evaluation of Dosing Interval of Higher Doses of Ranibizumab Completed NCT00533520 Phase 4 ranibizumab
33 Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed NCT00504959 Phase 4 ranibizumab
34 Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Completed NCT00473642 Phase 4 Ranibizumab;Verteporfin;Verteporfin
35 Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Recruiting NCT02769702 Phase 4 Acthar
36 Study of the Effectiveness of Ozurdex for the Control of Uveitis Recruiting NCT02049476 Phase 4 Dexamethasone pellet
37 Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization Recruiting NCT03042871 Phase 4 0.5mg intravitreal ranibizumab
38 Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis Recruiting NCT03066869 Phase 4 H.P. ACTHAR GEL
39 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
40 Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3) Active, not recruiting NCT02320474 Phase 4 Aflibercept
41 A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU Active, not recruiting NCT03020992 Phase 4 Certolizumab Pegol
42 Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Not yet recruiting NCT01939691 Phase 4 Difluprednate;Nepafenac;Prednisolone acetate
43 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
44 Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis Terminated NCT00918554 Phase 4 Methotrexate;Placebo
45 An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD Terminated NCT00327470 Phase 4 Pegaptanib Sodium 0.3 mg
46 Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy Withdrawn NCT01666236 Phase 4
47 Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial) Unknown status NCT00348153 Phase 2, Phase 3 Adalimumab
48 Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks Unknown status NCT00599820 Phase 3 Intravitreal Bevacizumab
49 Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy Unknown status NCT00344617 Phase 3 Bevacizumab (tradename: Avastin)
50 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3

Search NIH Clinical Center for Uveal Diseases

Genetic Tests for Uveal Diseases

Anatomical Context for Uveal Diseases

MalaCards organs/tissues related to Uveal Diseases:

Eye, Endothelial, Liver, Testes, Skin, T Cells, Bone

Publications for Uveal Diseases

Articles related to Uveal Diseases:

# Title Authors Year
Golden retriever cystic uveal disease: a longitudinal study of iridociliary cysts, pigmentary uveitis, and pigmentary/cystic glaucoma over a decade in western Canada. ( 26119416 )
Cytokines: their role in uveal disease. ( 9349412 )
A-mode echography in the diagnosis of uveal disease. ( 880517 )
Methotrexate treatment of uveal disease. ( 5904740 )
Retinal lesions associated with uveal disease. I. ( 13372709 )
The influence of hypersensitivity on endogenous uveal disease. ( 20288588 )
The influence of hypersensitivity on endogenous uveal disease. ( 20279194 )
Concerning the Use of Diphtheria Antitoxin in Post-Operative Infections and Acute Uveal Disease. ( 16692610 )

Variations for Uveal Diseases

Expression for Uveal Diseases

Search GEO for disease gene expression data for Uveal Diseases.

Pathways for Uveal Diseases

GO Terms for Uveal Diseases

Sources for Uveal Diseases

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....